Truist Securities lowers Biogen (NASDAQ:BIIB) price target from $350 to $340

By / / Biogen, Truist Financial

Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $350 to $340.

Scroll to Top